Katsumichi Fujimaki

Fujisawa, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 79 publications

Systemic CD5-Positive Diffuse Large B-cell Lymphoma Preceded by Intravascular Large B-cell Lymphoma-like Features in the Prostate: A Case Report.

Systemic CD5-Positive Diffuse Large B-cell Lymphoma Preceded by Intravascular Large B-cell Lymphoma-like Features in the Prostate: A Case Report.

Journal: Internal medicine (Tokyo, Japan)

Published: May 24, 2026

ELTS Score and Early "Warning" Define a Two-Stage Risk Framework for Failure-Free Survival in Chronic-Phase CML.

ELTS Score and Early "Warning" Define a Two-Stage Risk Framework for Failure-Free Survival in Chronic-Phase CML.

Journal: Blood advances

Published: May 12, 2026

Treatment-Free Remission and Immune Profiling after Frontline Second-Generation TKI Therapy in CML.

Treatment-Free Remission and Immune Profiling after Frontline Second-Generation TKI Therapy in CML.

Journal: Blood advances

Published: May 05, 2026

Delayed response with peripheral blood CD8+ T cell expansion during elranatamab therapy in relapsed/refractory multiple myeloma

Delayed response with peripheral blood CD8+ T cell expansion during elranatamab therapy in relapsed/refractory multiple myeloma

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: March 29, 2026

Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE-STOP219 study.

Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE-STOP219 study.

Journal: British journal of haematology

Published: March 12, 2026

Long-term outcomes of low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase: an extended follow-up of the DAVLEC phase 2 trial.

Long-term outcomes of low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase: an extended follow-up of the DAVLEC phase 2 trial.

Journal: Blood cancer journal

Published: February 14, 2026

Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs.

Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs.

Journal: Blood advances

Published: January 13, 2026

Real-world effectiveness of fostamatinib in patients with immune thrombocytopenia: a single-center retrospective study.

Real-world effectiveness of fostamatinib in patients with immune thrombocytopenia: a single-center retrospective study.

Journal: International journal of hematology

Published: December 03, 2025

Five-year interim analysis of J-SKI: an observational study of TKI discontinuation in patients with CML in Japan.

Five-year interim analysis of J-SKI: an observational study of TKI discontinuation in patients with CML in Japan.

Journal: International journal of hematology

Published: December 03, 2025

Outcome of initial cord blood transplantation with FM80TBI as conditioning regimen for acute myeloid leukemia.

Outcome of initial cord blood transplantation with FM80TBI as conditioning regimen for acute myeloid leukemia.

Journal: Annals of hematology

Published: July 05, 2025

Delayed Methotrexate Elimination Following High-dose Methotrexate Prophylaxis in High-risk Diffuse Large B-cell Lymphoma.

Delayed Methotrexate Elimination Following High-dose Methotrexate Prophylaxis in High-risk Diffuse Large B-cell Lymphoma.

Journal: Internal medicine (Tokyo, Japan)

Published: March 16, 2025

Preconditioning intervention prior to allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia.

Preconditioning intervention prior to allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia.

Journal: Experimental hematology

Published: December 05, 2024

Showing 1-12 of 79

Last Updated: 09/26/2026